Supamit Chunsutthiwat

Suggest Changes
Learn More
BACKGROUND The Thai Phase III Trial of ALVAC-HIV and AIDSVAX B/E showed an estimated vaccine efficacy (VE) of 31% to prevent acquisition of human immunodeficiency virus (HIV). Here we evaluated the(More)
  • 1